larotrectinib,entrectinib
bayer,roche
['larotrectinib', 'sclc', 'lcsm,(-blcsm)', 'entrectinib', 'nsclc']
#asco22 closes with a comment on reimbursement for entrectinib or larotrectinib in #ntrk nsclc and says it is "crazy" to not reimburse based on efficacy and that waiting for a randomized trial in this rare subtype is inappropriate. #lcsm 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him